Advanced glycation and oxidation products in patients with atherosclerosis;Produkty pokročilé glykace a oxidace u pacientů s aterosklerózou

Casopis Lekaru Ceskych

Volumn 144, Issue 6, 2005, Pages 385-390

  Kalousová, Marta ^a,b   Zak A ^a   Soukupova J ^a   Stipek S ^a   Malbohan, I M ^a   Zima, T ^a   Poledne, Rudolf ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b VFN ^*  (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Advanced glycation end products; Advanced oxidation protein products; AGEs; AOPP; Atherosclerosis; Carboxymethyllysine; Oxidative stress; Statin

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HUMAN; LIPID METABOLISM; OXIDATION; OXIDATIVE STRESS; SPECTROPHOTOMETRY; ARTERIOSCLEROSIS; BLOOD; FEMALE; MALE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION;

ARTERIOSCLEROSIS; BLOOD PROTEINS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 20644445854     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Makita, Z., Vlassara, H., Cerami, A., Bucala, R.: Immunochemical detection of advanced glycosylation end products in vivo. J. Biol. Chem., 1992, 267, s. 5133-5138.
2. Horiuchi, S.: The liver is the main site for metabolism of circulating advanced glycation end products. J. Hepatol., 2002, 36, s. 123-125.
3. Maillard, L. C.: Action des acides amines sur les sucres; formacion des melaniodines par voie methodique. CR. Acad. Sci., 1912, 154, s. 66-68.
4. Miyata, T., Maeda, K., Kurokawa, K., van Ypersele de Strihou, C.: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol. Dial. Transplant., 1997, 12, s. 255-258.
5. Miyata, T., Kurokawa, K., van Ypersele de Strihou, C.: Advanced glycation and lipoperoxidation products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J. Am. Soc. Nephrol., 2000, 11, s. 1744-1752.
6. Vlassara, H.: Recent progress in advanced glycation end products and diabetic complications. Diabetes., 1997, 46, s. 19-25.
7. Šebeková, K., Kupčová, V., Schinzel, R., Heidland, A.: Markedly elevated levels of plasma glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J. Hepatol., 2002, 36, s. 66-71.
8. Miyata, T., Ueda, Y., Schinzato, T. et al.: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J. Am. Soc. Nephrol., 1996, 7, s. 1198-1206.
9. Miyata, T., van Ypersele de Strihou, C., Imasawa, T. et al.: Glyoxylase 1 deficieny is associated with an unusual level of advanced glycation end products in hemodialyzed patient. Kidney Int., 2001, 60, s. 2351-2359.
10. Yan, S. D., Schmidt, A. M., Anderson, G. M. et al.: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem., 1994, 269, s. 9889-9897.
11. Bierhaus, A., Hofmann, M. A., Ziegler, R., Nawroth, P, P.: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus 1. The AGE concept. Cardiovasc. Res., 1998, 37, s. 586-600.
12. ε- (carboxymetyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem., 1999, 274, s. 31740-31749.
13. Witko-Sarsat, V., Friedlander, M., Capeillere-Blandin, C. et al.: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int., 1996, 49, s. 1304-1313.
14. Witko-Sarsat, V., Nguyen-Khoa, T., Jungers, P. et al.: Advanced oxidation protein products as novel molecular basis of oxidative stress in uremia. Nephrol. Dial. Transplant., 1999, 14, s. 76-78.
15. Capeillare-Blandin, C., Gausson, V., Deschamps-Latscha, B., Witko-Sarsat, V.: Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochem. Biophys. Acta., 2004, 1689, s. 91-102.
16. Witko-Sarsat, V., Friedlander, M., Nguyen-Khoa, T. et al.: Advanced oxidation protein products as novel mediator of inflammation and monocyte activation in chronic renal failure. J. Immunol., 1998, 161, s. 2524-2532.
17. Kalousová, M., Zima, T., Tesař, V. et al.: Relationship between advanced glycation end products, inflammatory markers/acute phase reactants and some autoantibodies in chronic hemodialysis patients. Kidney Int. Suppl., 2003, 63, s. 62-64.
18. Kaneda, H., Taguchi, J., Ogasawara, K. et al.: Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis., 2002, 162, s. 221-225.
19. Henle, T., Deppisch, R., Beck, W. et al.: Advanced glycated end products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogenity of AGE coumpound. Nephrol. Dial. Transplant., 1999, 14, s. 1968-1975.
20. Munch, G., Kies, R., Wessel, A. et al.: Determination of advanced glycation end products in serum by flourescence spectroscopy and competetive ELISA. Eur. J. Clin. Chem. Clin. Biochem., 1997, 35, s. 669-677.
21. Peppa, M., Uribarri, J., Vlassara H.: The role of advanced glycation end products in the development of atherosclerosis. Curr. Diab. Rep., 2004, 4, s. 31-36.
22. Meng, J., Sakata, N., Takebayashi, S. et al.: Glyoxidation in aortic collagen from STZ-induced diabetic rats and itsrelevance to vascular damage. Atherosclerosis., 1998, 136, s. 355-365.
23. Alderson, N. L., Chachic, M. E., Yousef, N. N. et al.: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int., 2003, 63, s. 2123-2133.
24. ε-(carboxymetyl)lysine, is a product of both lipid peroxidation and glycation reaction. J. Biol. Chem., 1996, 271, s. 9982-9986.
25. Baynes, J. W., Thorpe, S. R.: Glyoxidation and lipoxidation in atherosclerosis. Free Radic. Biol. Med., 2000, 28, s. 1708-1716.
26. Weiss, M. F., Erhard, P., Kader-Attia, F. A. et al.: Mechanisms of formation of glycoxidation products in end-stage renal disease. Kidney Int., 2000, 57, s. 2571-2585.
27. Saxena, A. K., Saxena, P., Wu, X. et al.: Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active cooper binding: relevance to disease of glycoxidative stress. Biochem. Biophys. Res. Commun., 1999, 260, s. 332-338.
28. Sakata, N., Imanaga, Y., Meng, J. et al.: Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerosis lesions. Atherosclerosis., 1998, 141, s. 61-75.
29. Sakata, N., Imanaga, Y., Meng, J. et al.: Increased advanced glycation end products in atherosclerosis lesions of patients with end-stage renal disease. Atherosclerosis., 1999, 142, s. 67-77.
30. Dworacka, M., Winiarska, H., Szymanska, M. et al.: Serum N-epsilon-(carboxymetyl)lysine is elevated in nondiabetic coronary heart disease patients. J. Basic. Clin. Physiol. Pharmacol., 2002, 13, s. 201-213.
31. Wooods, A. A., Linton, S. M., Davies, M. J.: Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerosis plaques. Biochem. J., 2003, 370, s. 729-735.
32. Drueke, T., Witko-Sarsat, V., Massay, Z. et al.: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation., 2002, 106, s. 2212-2217.
33. Kalousová, M., Šrha, J., Zima, T.: Advanced glycation end products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res., 2002, 51, s. 597-604.
34. Galler, A., Muller, G., Schinzel, R. et al.: Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determinated by flourescence spectroscopy and N-epsilon-(carboxymethyl)lysine ELISA. Diabetes Care., 2003, 26, s. 2609-2615.
35. Januszewski, A. S., Alderson, N. L., Metz, T. O. et al.: Role of lipids in chemical modification of proteins and development of complications in diabetes mellitus. Biochem. Soc. Trans., 2003, 31, s. 1413-1416.
36. Witko-Sarsat, V., Capeillere-Blandine, C., Descamps-Latscha, B.: Reply from the author. Kidney Int., 2004, 65, s. 340.
37. Hendrick, C. C., Thorpe, S. R., Fu, M. X. et al.: Glyacation impairs hodh-density lipoprotein function. Diabetologia., 2000, 43, s. 312-320.
38. Rosenson, R. S.: Statins in atherosclerosis: lipid lowering agent with antioxidant capabilities. Atherosclerosis., 2004, 173, s. 1-12.
39. Sumi, D., Hayashi, T., Thakur, N. K. et al.: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis., 2001, 155, s. 347-357.
40. Inoue, T., Hayashi, M., Takayanagi, K., Morooka, S.: Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis., 2002, 160, s. 369-376.
41. Okamoto, T., Yamagishi, S., Inagaki, Y. et al.: Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB., 2002, 16, s. 1928-1930.